TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.
TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.
TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells.
The neutron beam is aimed at the cancer patient’s tumors for about 30 minutes, and is combined with a boron-based substance that is injected into the patient intravenously and accumulates in the cancer cells.
BNCT is a particularly promising technique for treating cancers of the head and neck region that are difficult or impossible to treat using other types of therapy. The procedure has already been tested in Japan, the United States and other locales.